## Drug Safety Updates



## Supply Disruption alert: Glipizide (Minodiab<sup>®</sup>) 5mg tablets

## SORRY TEMPORARILY OUT OF STOCK

## September 2021

Pfizer are out of stock of glipizide (Minodiab<sup>®</sup>) 5mg tablets until mid-October 2021 due to increased demand. This has been caused by the withdrawal of certain brands of Glipizide 5mg tablets. The Department of Health and Social Care has issued the following advice to health care professionals:

- Prescribers will need to review all affected patients with insufficient supplies of glipizide and assess ongoing need. The risk of hypoglycaemia, age, frailty status, and the patient's HbA1c should be taken into consideration
- If ongoing treatment is required, consideration should be given to prescribing an alternative formulary approved sulfonylurea or glucose lowering medication as advised below:
  - Consider prescribing an equivalent dose of gliclazide immediate release tablets.
     Based on clinical experience, 5 mg of glipizide should be roughly equivalent to 80 mg of gliclazide.
  - If gliclazide immediate release tablets are not appropriate, consider prescribing an alternative sulfonylurea.
  - Patients with monogenic diabetes (MODY) should remain on an equivalent dose of an alternative sulfonylurea. (MODY-an autosomal dominant, genetic form of diabetes where a change in a single gene is responsible for glucose dysregulation, where patients would have been identified through genetic testing).
  - If alternative glucose-lowering medications may be more appropriate, discuss these options with the patient, considering their individual preferences, characteristics, and comorbidities.
  - Where necessary contact specialists in secondary care for advice on management options.
  - Arrange for appropriate follow-up, monitoring and review
- When licensed glipizide tablets are resupplied, GP practices should review patients
  prescribed an alternative agent and discuss appropriate next steps and management.
- Patients should be counselled on potential side-effects and new dose regime if prescribing alternative glucose lowering medications.
  - Pfizer are out of stock of glipizide (Minodiab<sup>®</sup>) 5mg tablets until mid-October 2021 due to increased demand
  - The Department of Health and Social Care has issued guidance to health care professionals
  - Patients should be counselled on potential side-effects and new dose regime if prescribing alternative glucose lowering medications

For further information, please contact the Medicines Management Team on 01282 644799 or 01254 282087 email elccg.adminmmt@nhs.net